NOT KNOWN FACTUAL STATEMENTS ABOUT IL-2 THERAPY FOR MELANOMA

It is actually perfectly understood that IL-2 is often a pleiotropic cytokine positioned within the crossroads of T mobile activation and regulation. Therefore, it's essential to engineer an IL-2 molecule that is definitely biased toward effector cells bearing the intermediate affinity receptor, which include naïve and memory CD8+ T cells and NK c